Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis1,2,3,4,5,6,7
Introduction
Recently, the ITABIO (Italian board for the TAilored BIOlogic therapy) task force focused on the first-line biologic choice driving variables in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) to ensure the best results in terms of clinical outcome and safety [1]. However, data from clinical trials and national registries show that first-line biologics, either combined with methotrexate (MTX) or in monotherapy, should be discontinued in approximate 30–40% of the patients due to inadequate response or adverse events in the majority of the cases [2], [3], [4]. Overall, biologic survival is lower in RA compared with PsA and AS [5], though in all the three disorders the discontinuation rate seems time-dependent with a progressive increase related to the length of follow-up [6].
To date, nine biologics including interleukin-6 (IL-6) inhibitor tocilizumab (TCZ), anti-CD20 rituximab (RTX), anti-interleukin-1 (IL-1) anakinra (ANK), anti-CD28 abatacept (ABA), and anti-tumor necrosis factor alpha agents (anti-TNFs) adalimumab (ADA), etanercept (ETN), infliximab (IFX), golimumab (GOL), certolizumab pegol (CTP), and, limited to Europe, infliximab biosimilar (bio-IFX), are approved for RA treatment, anti-TNFs, anti-interleukin-12–23 (IL-12–23) ustekinumab (UTK), and anti-interleukin-17 (IL17) secukinumab (SCK) for PsA, while only anti-TNFs and SCK are licensed for AS.
Compared to the first-line biologic therapies, the second-line ones have been less investigated in terms of effectiveness, safety, and drug survival. Moreover, controlled trials (RCTs) and current recommendations do not provide sufficient indication concerning the best strategy between switching and swapping among biologics [1]. In absence of well-defined response predictors, several variables may drive the second biologic choice in clinical practice, including the data on the efficacy, safety, disease severity, infection risk, patient׳s age and gender, route of administration, and comorbidities.
Section snippets
Objective
The aim of present paper was to provide appropriate indications for the best choice of second-line biologic therapy in patients with RA, PsA, and AS through a systematic review of the literature.
Methods
As previously described [1], a multidisciplinary expert panel, the Italian board for the TAilored BIOlogic therapy (ITABIO), including specialists in rheumatology (M.B., F.C., E.F., R.F., S.G., and L.N.), infectious diseases (D.G. and F.B.), and, immunology (M.M.), was constituted to review the literature on the existing evidence on the efficacy, safety, and the different variables influencing the second-line biologic choice in patient with RA, AS, n-rx-AxSpA, and PsA. Each ITABIO member
Literature search
The literature review was made using PubMed database to identify English-language articles related to the previously mentioned topics. Data were extracted from available recommendations, systematic reviews, and meta-analyses, RCTs, national registries of biologics, national healthcare databases, and post-marketing surveys. When these source data were not available for specific topics, the evidence was derived from open-label studies on variable sample-size clinical series.
The following drugs
General indications
As previously stated [1], some choice driving variables, including the patients׳ preference for self-administered subcutaneous route with the longest administration intervals, the indication for anti-TNF monotherapy in potential childbearing women, and its interruption at positivity of pregnancy test, are valid also for the second biologic choice after interruption of the first for inefficacy or adverse events occurrence.
Choice of the second or third biologic agent in RA
The first choice of biologic therapy for the treatment of synthetic DMARD
Conclusion
Though the lack of head-to-head trials reduces the strength of our recommendations for the proper second-line biologic choice in RA, PsA, and AS, the available data from the literature provide useful indications for the optimization of therapy in patients failing the first biologic agent, and offer the opportunity to make some final considerations. First, as previously underlined, the rather relevant percentage of at least 20% of patients with RA PsA, and AS failing the first biologic is
References (116)
- et al.
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis
Semin Arthritis Rheum
(2016) - et al.
Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
Lancet
(2009) - et al.
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
Lancet
(2016) - et al.
Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry
Autoimmun Rev
(2010) - et al.
Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers
Joint Bone Spine
(2015) - et al.
Measuring psoriatic disease in clinical practice. An expert opinion position paper
Autoimmun Rev
(2015) - et al.
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Lancet
(2015) - et al.
Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study
Semin Arthritis Rheum
(2008) - et al.
Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study
Semin Arthritis Rheum
(2011) - et al.
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases
Rheumatology (Oxford)
(2016)
Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry
Arthritis Rheum
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry
Ann Rheum Dis
Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL
Clin Rheumatol
Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides
Drug Dev Res
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial
Arthritis Rheum
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
N Engl J Med
Infliximab and methotrexate in the treatment of rheumatoid arthritis
N Engl J Med
When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?
Ann Rheum Dis
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
Ann Rheum Dis
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study
Arthritis Res Ther
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Arthritis Res Ther
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
Arthritis Res Ther
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects
Ann Rheum Dis
Outcomes of switching anti-TNF drugs in rheumatoid arthritis—a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN)
Clin Rheumatol
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
Ann Rheum Dis
Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice
Rheumatology (Oxford)
Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study
Arthritis Rheum
Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody
Rheumatology (Oxford)
Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register
Rheumatology (Oxford)
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
Ann Rheum Dis
Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
Arthritis Res Ther
Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study
Ann Rheum Dis
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Ann Rheum Dis
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
N Engl J Med
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Arthritis Rheum
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies
Ann Rheum Dis
Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial
J Am Med Assoc
Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis
Ann Rheum Dis
The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review
Rheumatology (Oxford)
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
Biologics
B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents
Arthritis Rheum
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
Scand J Rehabil Med
Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
Arthritis Care Res
Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis
J Rheumatol
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study
Ann Rheum Dis
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
Ann Rheum Dis
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
Arthritis Res Ther
Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies
Rheumatology (Oxford)
Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry
Clin Rheumatol
Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice
Clin Rheumatol
Cited by (0)
- 1
On behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO) members: Fabrizio Cantini Laura Niccoli.
- 2
On behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO) members:, Ennio Giulio Favalli.
- 3
On behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO) members: Maurizio Benucci.
- 4
On behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO) members:, Serena Guiducci.
- 5
On behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO) members: Rosario Foti.
- 6
On behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO) members: Marta Mosca.
- 7
On behalf of the Italian board for the TAilored BIOlogic therapy (ITABIO) members: Delia Goletti.